Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | What remaining unmet needs are there in oligometastatic prostate cancer?

Alexander Sherry • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer

Alexander Sherry, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the unmet needs in oligometastatic prostate cancer, highlighting the need for more translational work to identify patients most likely to benefit from specific therapies and to balance disease control with quality of life. Dr Sherry emphasizes the importance of refining the definition of oligometastatic disease, including the use of modern imaging modalities and novel biomarkers, to better tailor treatment strategies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexander Sherry

EXTEND: Phase II trial of MDT plus ADT in oligometastatic prostate cancer
3:32
EXTEND: Phase II trial of MDT plus ADT in oligometastatic prostate cancer
Alexander Sherry • 13 Feb 2025
The future of MDT in oligometastatic prostate cancer
0:52
The future of MDT in oligometastatic prostate cancer
Alexander Sherry • 13 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals